Associated tags: Health, NYSE, Baxter International, Medical Devices, Hospitals, Medical Supplies, Biotechnology, Surgery, Patient, Baxter, Health Technology, General Health, Pharmaceutical
Medical Supplies,
Medical Devices,
Health,
Pharmaceutical,
Optical,
Biotechnology,
Sale,
FDA,
Baxter,
Pharmacist,
Sodium chloride,
Food,
Growth,
LVP,
SYR,
Novum,
Baxter International,
Nursing,
Patient,
EPS,
CDT,
BPS,
GAAP,
Food and Drug Administration,
Vasopressin Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.
- Regardless of the selected path, Baxter currently expects the separation of its Kidney Care business to take place in the second half of 2024.
- For full-year 2024: Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis.
- A webcast of Baxter’s first-quarter 2024 conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on May 2, 2024.
Biotechnology,
Surgery,
Health,
Pharmaceutical,
Cardiology,
FDA,
Baxter,
USP,
Sodium chloride,
Injection,
Blood pressure,
Baxter International,
Anesthesia,
Patient,
Regadenoson,
Antimalarial medication,
Infection,
Hypotension,
Catecholamine,
Vasopressin,
Vancomycin,
Pharmaceutical industry “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
Key Points:
- “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
- For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
- Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
- Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.
Retrieved on:
Wednesday, April 10, 2024
Surgery,
Medical Devices,
Medical Supplies,
Hospitals,
Health Technology,
Practice Management,
Biotechnology,
Health,
General Health,
Baxter International,
Central Time,
Webcast,
Medtech Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time.
- To participate in this conference call please follow this link https://registrations.events/direct/Q4I215737 to pre-register for the call and receive the call information.
- This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com .
- The conference call will be recorded by Baxter and is copyrighted material.
Technology,
Medical Devices,
Hospitals,
FDA,
Health Technology,
Software,
Biotechnology,
General Health,
Pharmaceutical,
Health,
SYR,
Novum,
LVP,
EMR,
Patient,
State,
Food and Drug Administration,
CQI,
Hospital,
Pharmacist,
Baxter International,
Computer security,
Safety,
Nursing,
Baxter,
Medicine,
Pump,
Food,
Medical device Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
Key Points:
- Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
- Offering the Novum IQ LVP in the U.S. demonstrates Baxter’s commitment to continued innovation in advancing infusion therapy.
- “The Novum IQ platform represents a meaningful shift in how connected and intelligent infusion therapy can impact the way clinicians provide care.
- IQ Enterprise Connectivity Suite, a scalable all-in-one server, integration engine and software application platform, designed to simplify infusion system connectivity for the Novum IQ Infusion Platform.
Retrieved on:
Wednesday, March 27, 2024
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.
- As always, whether or not a stockholder plans to attend the virtual 2024 Annual Meeting, all stockholders of record are encouraged to vote their shares prior to the 2024 Annual Meeting by one of the methods described in the proxy materials for the 2024 Annual Meeting.
- A list of Baxter's stockholders of record will be available for examination by stockholders on the 2024 Annual Meeting website during the meeting.
- Stockholders that have not voted their shares prior to the 2024 Annual Meeting will be able to vote their shares electronically at the 2024 Annual Meeting by clicking “Vote Here” on the meeting website.
Retrieved on:
Thursday, February 29, 2024
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024.
- Joel Grade, Baxter’s chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time.
- The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Friday, May 31, 2024.
Retrieved on:
Monday, February 12, 2024
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
- The dividend is payable on April 1, 2024, to stockholders of record as of March 1, 2024.
- The indicated annual dividend rate is $1.16 per share of common stock.
Retrieved on:
Thursday, February 8, 2024
Medical Supplies,
Health,
Medical Devices,
General Health,
Pharmaceutical,
Optical,
Biotechnology,
EPS,
Task force,
DNA,
Nursing care plan,
Piperacillin,
Noise,
Corporate social responsibility,
FDA,
Corporation,
Medicine,
UN,
Dow Jones,
EMR,
Failure,
Baxter International,
Growth,
Perioperative,
TCFD,
DJSI,
Patient,
Tazobactam,
Centrella,
Skin,
Thrombin,
Risk,
Warburg Pincus,
Acute liver failure,
Galaxy,
PD,
NuVasive,
Peritoneal dialysis,
Risk management,
Advent International,
BPS,
Sale,
Eye,
CST,
Pharmaceutical industry Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024.
- For full-year 2023, net income attributable to Baxter on a U.S. GAAP basis totaled $2.66 billion, or $5.25 per diluted share.
- In 2023, the company was named to the Dow Jones Sustainability Index (DJSI) North America, which has included Baxter each year since it launched in 2005.
- For full-year 2024: Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.
Retrieved on:
Thursday, January 18, 2024
Teens,
Medical Devices,
Surgery,
Hospitals,
Health Insurance,
Family,
University,
Consumer,
Health,
Education,
ACT,
Student,
UCL,
Baxter,
Trinity College,
Refugee,
Employment,
Faculty,
Partnership,
Science,
Medtech,
Trinity College Dublin,
Baxter International,
Dublin City University,
Nursing Baxter’s funding will support 10 students in total over the 2023/2024 and 2024/2025 academic years.
Key Points:
- Baxter’s funding will support 10 students in total over the 2023/2024 and 2024/2025 academic years.
- “Through our Activating Change Today (ACT) initiative, Baxter has proudly created several programs that support students in the U.S. who are pursuing health and science degrees.
- The scholarships will be awarded based on financial need to UK students of Black-African or Black-Caribbean descent.
- Trinity College Dublin will offer three scholarships to undergraduate ethnic minority students through its Trinity Access Program, which aims to increase participation in higher education by students from underrepresented groups and communities in Ireland.
Retrieved on:
Thursday, January 4, 2024
Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time.
Key Points:
- Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time.
- To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information.
- This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com .
- The conference call will be recorded by Baxter and is copyrighted material.
